Needham Thinks Steris’ Stock is Going to Recover

Needham analyst Michael Matson maintained a Buy rating on Steris (STEResearch Report) today and set a price target of $248.00. The company’s shares closed last Thursday at $202.44, close to its 52-week low of $192.40.

According to, Matson is a 3-star analyst with an average return of 2.0% and a 45.6% success rate. Matson covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Cardiovascular Systems, and Zimmer Biomet Holdings.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Steris with a $256.00 average price target.

See the top stocks recommended by analysts >>

Steris’ market cap is currently $20.26B and has a P/E ratio of 84.55.

Based on the recent corporate insider activity of 56 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of STE in relation to earlier this year. Earlier this month, Richard Breeden, a Director at STE bought 3,218 shares for a total of $104,134.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

STERIS Plc (Ireland) engages in the manufacture of medical and surgical equipment. The company was founded on December 22, 2016 and is headquartered in Dublin, Ireland.

Read More on STE:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More